Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
44 results about "Retina Neovascularization" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Injectable Combination Therapy for Eye Disorders
InactiveUS20090220572A1Compounds screening/testingPowder deliveryLiquid mediumRetinal neovascularization
Owner:POTENTIA PHARMA INC
Compositions and methods for treatment of neovascular diseases
The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient.
Owner:THE SCRIPPS RES INST
Compstatin and analogs thereof for eye disorders
ActiveUS20070238654A1Inhibit expressionImprove in vivo stabilityCompounds screening/testingOrganic active ingredientsDiseaseRetinal neovascularization
The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and / or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
Owner:APELLIS PHARMA
Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
InactiveUS20160159893A1Stopping abnormal blood vessel growthExtended half-lifeLaser surgerySenses disorderDiseaseRetina
The present invention relates to the use of a VEGF antagonist in the treatment of retinal neovascular disorders in infants. In particular, the invention provides a method for treating an infant having retinopathy of prematurity (ROP), wherein said method comprises administering to the eye of an infant a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The term “infant” is typically used to refer to young children from birth up to the age of 12 months. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops.
Owner:NOVARTIS AG
Human profibrinolysin kringle 5 deletion mutation recombinant polypeptide
InactiveCN1451746AReduce leakageHas a specific inhibitory effectBacteriaEnzymesProfibrinolysinEscherichia coli
A human plasminogen Kringle 5 deleted mutant recombinant polypeptide for treating the retinopath, such as vascular hyperplasia and angiorrhea, is prepared through removing 15 amino acid residue from K5 molecule while retaining 3 disulfide bond, expressing in colibacillus, and purifying by affinity chromatography.
Owner:QIYUAN BIOLOGICAL SCI & TECH GUANGZHOU CITY
Application of integrin blocker in preparation of medicaments for treating ocular neovascular diseases
ActiveCN102205110APromote formationGrowth inhibitionSenses disorderPeptide/protein ingredientsOphthalmologyPolyethylene glycol
The invention relates to the medical field, in particular to an integrin blocker with integrin affinity and combining capacity. The integrin blocker comprises three polypeptides which can be used for preventing and treating ocular neovascular diseases. The polypeptides of the integrin blocker particularly contain polypeptide I: Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp, polypeptide II: Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, and polyethylene glycol modified polypeptide III: mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp. The integrin blocker can be used for treating ocular neovascular diseases including corneal ocular neovascular diseases, iridal ocular neovascular diseases, choroidal ocular neovascular diseases, retinal ocular neovascular diseases and the like.
Owner:CHINA PHARM UNIV
Integrin blocking agent polypeptide and applications of the same in preparation of drugs for treatment of neovascular eye diseases
ActiveCN104327169ASuppress generationInhibition formationSenses disorderPeptide/protein ingredientsIntegrin ligandArg-Gly-Asp
The present invention discloses an integrin blocking agent polypeptide and applications of the same in preparation of drugs for treatment of neovascular eye diseases, and belongs to the field of medicine. The integrin blocking agent polypeptide comprises a polypeptide I Arg-Gly-Asp-Gly-Gly-Gly-Gly-Phe- Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala and a polypeptide II Phe-Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Al a-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp, wherein the polypeptide I is modified with the integrin ligand sequence (Arg-Gly-Asp-Gly-Gly-Gly-Gly). The integrin blocking agent polypeptide can be used for treatments of iridal neovascular eye diseases, choroidal neovascular eye diseases, retinal neovascular eye diseases or corneal neovascular eye diseases and other neovascular eye diseases.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Method for constructing disease model on basis of gene operation strategy and application
ActiveCN110100788AWide range of usesIncrease the speed of proliferationAnimal husbandryCerebellar ataxiaVascular endothelium
The invention discloses a method for constructing a disease model on the basis of a gene operation strategy and application, and relates to the technical field of biology. According to the method, anEmc3 gene is prevented from being expressed in vascular endothelial cells or cerebellum Purkinje cells of a target animal through a gene operation technology. By using the method, a disease animal model showing typical characteristics of retinal neovascularization diseases or cerebellar ataxia diseases can be obtained. The method provides a new thought or strategy for constructing a retinal neovascularization disease model or a cerebellar ataxia disease model. In addition, the disease model obtained by means of the method also provides a model basis for science researchers to study the retinalneovascularization diseases and screen medicines for treating the retinal neovascularization diseases or the cerebellar ataxia diseases.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL
Application of transthyretin in aspects of entering eye and preparing drop
ActiveCN111437398AGood biocompatibilityHigh biosecuritySenses disorderAntibody mimetics/scaffoldsDiseaseAmino acid composition
The invention provides application of transthyretin in the aspect of serving as a carrier for a protein and / or polypeptide drug to enter an eye through an eye barrier. The transthyretin is a protein consisting of amino acid as shown in SEQ ID NO:1 or a mutation thereof or a modification thereof. The invention further provides application of the transthyretin and / or a fusion protein of the transthyretin and a drug to preparation of a drop and a drop. The drug is the protein and / or polypeptide drug. The transthyretin has good biocompatibility and safety in human bodies, can effectively convey aforeign protein and / or polypeptide into the eye and achieves an effect of treating eye diseases. In an eye dropping manner, when the eye diseases such as DR (Diabetic Retinopathy), AMD (Age-related macular degeneration), ROP (Retinopathy of Prematurity) and the like are treated, the transthyretin can enter a vitreous body and eye ground across a cornea barrier so as to obviously inhibit eyeball retina leakage, obviously reduce the number of retinal new blood vessels and effectively relieve the pathological phenomena of the eye diseases.
Owner:易舟(上海)生物医药有限公司
Treatment of Macular Degeneration
InactiveUS20100143346A1Reducing angiogenesisInhibits agonist activityAntibacterial agentsBiocideRetinal neovascularisationOcular disease
An agent having progesterone antagonist properties may be used to treat eye conditions associated with pathological blood vessel formation, for example age-related macular degeneration, choroidal neovascularisation, retinal neovascularisation or corneal neovascularisation. The agent may be mifepristone.
Owner:SUMMIT
Therapeutic Administration Of The Scrambled Anti-Angiogenic Peptide C16Y
Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.
Owner:DEPT OF HEALTH & HUMAN SERVICES SEC OF GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE
Compositions and methods for treatment of neovascular diseases
InactiveUS20060003933A1Good synergistic effectBiocideSenses disorderAbnormal tissue growthTryptophan
The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient.
Owner:THE SCRIPPS RES INST
Method for constructing retinal neovascularization disease animal model by using gene manipulation technology, cultivation method and application
ActiveCN111500638AConducive to promoting progressRich varietyStable introduction of DNAAnimal husbandryDiseaseVascular endothelium
The invention discloses a method for constructing a retinal neovascularization disease animal model by using a gene manipulation technology, a cultivation method and application, and relates to the technical field of gene editing. According to the construction method disclosed by the invention, the Ctnnnd1 gene in the vascular endothelial cells of the target animal is not expressed or the expression of the Ctnnd1 gene is inhibited by utilizing a gene manipulation technology. By means of the method, the animal model of the retinal neovascularization disease can be obtained, the variety of the animal model of the retinal neovascularization disease is enriched, more diversified model selections are provided for related research of the retinal neovascularization disease, and scientific research of the retinal neovascularization disease, development of related treatment drugs and the like are promoted.
Owner:SICHUAN PROVINCIAL PEOPLES HOSPITAL
Construction method of retinal angiomatous proliferation (RAP) and/or retinal capillary hemangioma (RCH) model
The invention discloses a retinal angiomatous proliferation (RAP) and / or retinal capillary hemangioma (RCH) mouse model; the model is a gene knockout mouse obtained by crossing a Cre mouse, a Rb floxed mouse and a Vhl floxed mouse.A large number of new blood vessels exist on the peripheral retina of an Rb / Vhl double knockout (DKO) mouse model, the blood vessels penetrate an entire layer, and a dense capillary network is formed and the normal layered structure of a retinal three-layer capillary network is lost.The phenotypes are more severe than the retinal neovascularization in an RAP model inthe prior art; some new blood vessels still exist on the peripheral retina of Rb / P107 / Vhl triple knockout (TKO) mice, but significant phase III RAP and RCH lesions are formed under the retina.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Construction method and application of retinal vasculopathy model
ActiveCN112980879APerfect theoretical basisFermentationAnimals/human peptidesDiseaseVascular endothelium
The invention discloses a construction method and application of a retinal vasculopathy model, and relates to the field of eye disease research. The Jup gene in vascular endothelial cells of a target animal is not expressed or is inhibited in expression through a genetic engineering technique, so that the target animal shows typical retinal neovascularization disease characteristics. The target animal can be used as a retinal neovascularization disease model for research of the retinal neovascularization disease, can also help to clarify the pathogenesis process and mechanism of the retinal neovascularization disease and enrich the theoretical basis of retinal neovascularization, and provides a new target for treatment or prevention of the retinal neovascularization disease to assist research and development of retina neovascularization treatment means.
Owner:SICHUAN PROVINCIAL PEOPLES HOSPITAL
Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and / or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.
Owner:CUEVAS SANCHEZ PEDRO +7
Retinal neovascularization detection method and imaging method for color fundus image
ActiveCN111612856AEasy to detectImprove reliabilityImage enhancementImage analysisRetinal neovascularizationPrediction probability
The invention discloses a retinal neovascularization detection method for a color fundus image. The method comprises the steps of obtaining color fundus image data and performing preprocessing to obtain training data; constructing a deep learning network model for retinal neovascularization detection; training the deep learning network model by adopting the training data to obtain a retinal neovascularization detector; preprocessing the color fundus image data to be detected; adopting a retinal neovascularization detector to detect the preprocessed to-be-detected color eye fundus image data toobtain a prediction probability graph of pixels judged as retinal neovascularization in the to-be-detected color eye fundus image; and carrying out thresholding processing to obtain a final detectionresult of the retinal neovascularization in the to-be-detected color fundus image. The invention further discloses an imaging method comprising the retinal neovascularization detection method for thecolor fundus picture. The device is high in reliability, good in practicability and good in detection effect.
Owner:CENT SOUTH UNIV
Compositions and methods for treatment of neovascular diseases
The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient.
Owner:THE SCRIPPS RES INST
Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
Owner:CUEVAS SANCHEZ PEDRO +7
Method for constructing rat model for proliferative diabetic retinopathy (PDR)
PendingCN112602668AFit phenotypeLow costCompounds screening/testingAnimal husbandryDyslipidemiaDiabetes retinopathy
The invention belongs to the technical field of diabetic animal model construction, and particularly relates to a method for constructing a ZDF (Zucker diabetic fatty) rat model for proliferative diabetic retinopathy (PDR). The method for constructing the model with PDR comprises the following steps: carrying out high-fat and high-sugar diet feeding on ZDF rats, and inducing hyperglycemia formation and dyslipidemia to obtain the rat model for PDR. Experiments find that the rat model obtained by the method can be successfully constructed, the obtained model has obviously increased blood sugar, abnormal lipid metabolism, retinal neovascularization indicated by fundus angiography FFA, vitreous opacity, retinal inner layer thinning indicated by OCT, retinal inner layer thinning indicated by pathology, remarkable reduction of ganglion cells and alteration of garland-like loss of the outer nuclear layer, the modeling time is short, and the application prospect is excellent.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV +1
Compstatin and analogs thereof for eye disorders
The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and / or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
Owner:APELLIS PHARMA
Medicine for treating retinal neovascular diseases
The invention relates to a medicine for treating retinal neovascular diseases, which is prepared from nafamostat mesylate; moreover, antibodies of endotoxin molecules C3a and / or C5a of a complement system are selectively added in the medicine. According to the invention, the nafamostat mesylate is used for preparing the medicine for treating retinal neovascular diseases, wherein the nafamostat mesylate acts on complement way; in addition, antibodies of C3a and C5a polypeptides are added to the medicine to generate neutralization; therefore, the growth of retinal neovascular can be controlled more effectively. The prepared medicine can be a novel medicine for treating retinal neovascular diseases, thereby providing a new thought for clinically treating various retinal neovascular diseases.
Owner:SHANDONG EYE INST
Traditional Chinese medicine for treating proliferative diabetic retinophathy
InactiveCN104940754ALower eye pressureReduce thicknessSenses disorderMetabolism disorderDiabetes retinopathyLife quality
The invention belongs to the technical field of traditional Chinese medicine, in particular to traditional Chinese medicine for treating proliferative diabetic retinopathy. The traditional Chinese medicine comprises, by weight, 5-13 parts of American ginseng, 8-16 parts of radix pseudostellariae, 8-16 parts of atractylodes macrocephala koidz, 11-15 parts of Chinese yam, 8-16 parts of prepared rehmannia roots, 8-16 parts of fruits of Chinese wolfberry, 8-16 parts of glossy privet fruits, 8-16 parts of seeds of Chinese dodder, 5-13 parts of ligusticum wallichii, 5-13 parts of corydalis tuber, 8-16 parts of salviae miltiorrhizae, 5-13 parts of Rhizoma Sparganii, 1-3 parts of leeches, 5-13 parts of rhizoma arisaematis, 2-4 parts of rhizoma typhonii, 8-16 parts of semen cassiae and 8-16 parts of seeds of feather cockscomb. The traditional Chinese medicine can effectively reduce the intraocular pressure and the thickness of yellow spots of an affected eye, reduce the leakage area of retinal neovascularization, promote retinal neovascularization to gradually vanish, improve the vision of a patient and improve the life quality of the patient.
Owner:JINAN BANGWEN MEDICAL TECH
Treatment of retinal vascular disease using progenitor cells
InactiveCN109414460ASenses disorderPharmaceutical delivery mechanismVascular diseaseRetinal neovascularization
Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.
Owner:JANSSEN BIOTECH INC
Method for inducing retinal and choroidal neovascularization by AAV-VEGF (adeno-associated virus transduced-vascular endothelial growth factor)
The invention discloses a method for inducing retinal and choroidal neovascularization by AAV-VEGF (adeno-associated virus transduced-vascular endothelial growth factor), and the AAV-VEGF is applied to the animal body by a subretinal injection method. Through the way, according to the method for inducing the retinal and choroidal neovascularization by the AAV-VEGF, by subretinal injection of AAV-VEGF gene, retinal neovascularization hyperplasia can be promoted, meanwhile the retinal neovascularization induced by the AAV-VEGF can be maintained for a long term, the successful rate can reach over 98%, and diabetic fundus lesions or wet age-related maculopathy simulated retinopathy can be obtained.
Owner:JOINN LAB (SUZHOU) INC
Construction method and application of retinal neovascular disease model
Owner:SICHUAN PROVINCIAL PEOPLES HOSPITAL
Preparation method of high-activity recombinant protein
PendingCN113501857ASolve the problem of loss of biological activityHigh activityPeptide preparation methodsInterleukinsOrganic solventHigh activity
The invention relates to the technical field of recombinant protein purification, in particular to a preparation method of high-activity recombinant protein. The preparation method comprises the following steps: mixing an HPLC (High Performance Liquid Chromatography) purified sample of recombinant protein with a protein dissolving solution, and dissolving; mixing the dissolved sample with a renaturation solution, and carrying out renaturation treatment; and purifying the sample subjected to renaturation treatment by adopting an anion exchange chromatographic column to obtain the high-activity recombinant protein. According to the present invention, by improving the formulas of the protein dissolving liquid and the renaturation liquid, the problem that the recombinant protein purified by HPLC loses the biological activity is further solved, the high-activity and high-purity recombinant protein sample is prepared, and the method has characteristics of simple operation, no endotoxin and no organic solvent residue, and is suitable for retina neovascularization treatment.
Owner:沈阳百发科技有限公司 +2
Ophthalmic preparation as well as preparation method and application thereof
PendingCN114558112AGood treatment effectEffective treatmentSenses disorderHydroxy compound active ingredientsRetinal neovascularizationRetinal
Owner:易舟(上海)生物医药有限公司
Use of a VEGF antagonist in treating retinopathy of prematurity
InactiveCN105377890AInhibit progressPrevent increased systemic exposureLaser surgerySenses disorderRetinaTerm Infant
The present invention relates to the use of a VEGF antagonist in the treatment of retinal neovascular disorders in infants. In particular, the invention provides a method for treating an infant having retinopathy of prematurity (ROP), wherein said method comprises administering to the eye of an infant a VEG F antagonist that either does not enter or is rapidly cleared from the systemic circulation. The term infant is typically used to refer to young children from birth up to the age of 12 months. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops.
Owner:NOVARTIS AG
A method and application for constructing retinal neovascular disease model
Owner:SICHUAN PROVINCIAL PEOPLES HOSPITAL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com